缬沙坦联合泼尼松、吗替麦考酚酯治疗小儿难治性肾病综合征的近期疗效观察  

Clinical Study of Valsartan Combination Treatment with Mycophenolate Mofetil and Prednison in Refractory Nephropathy Syndrome

作　　者：李琳霞[1] 赵琳[1] 李艳红[1] 谢怀平[1] 吴洁[1] 

机构地区：[1]昆明医学院第二附属医院,云南昆明650101

出　　处：《中国医学创新》2015年第2期19-21,共3页Medical Innovation of China

摘　　要：目的:了解缬沙坦联合泼尼松、吗替麦考酚酯(MMF)治疗小儿难治性肾病综合征的疗效。方法:54例符合难治性肾病综合征诊断标准的患儿,随机选取36例为治疗组,采用缬沙坦联合泼尼松、吗替麦考酚酯(MMF)治疗12周,对照组18例,仅使用泼尼松、吗替麦考酚酯联合治疗,定期复查尿常规、24 h尿蛋白定量、肝、肾功能等,观察两组近期疗效。结果:治疗组治疗3个月后总有效率为94.5%,对照组为83.3%,两组疗效比较差异有统计学意义(P<0.05)。结论:缬沙坦联合泼尼松、MMF治疗小儿难治性肾病综合征具有更好的疗效。Objective：To explore the therapeutic effect of valsartan combination treatment with mycophenolate mofetil and prednison in refractory nephropathy syndrome.Method：54 patients with primary refractory nephropathy syndrome were randomly divided into treatment group and control group. 36 cases of treatment group were treated by valsartan combined with MMF and prednisone, and 18 cases of the control groups were only threated with MMF and prednisone.The blood test, 24 h quantitation of proteinuria, liver function and renal function periodically were observed. Result：3 months later,the total effective rate were 94.5% and 83.3% respectively.Conclusion： Valsartan combined with MMF and prednisone is effective on child primary refractory nephropathy syndrome.It is a kind of promising clinical treatment of this disease at present.

关 键 词：缬沙坦 泼尼松 吗替麦考酚酯 小儿难治性肾病综合征 

分 类 号：R726.9[医药卫生—儿科]